Psychiatry research · 2025
12-Month mirror study on the effectiveness and safety of six-month paliperidone palmitate in patients with schizophrenia: A Multicenter Andalusian Cohort (PAPSEM study).
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García-Jiménez Jesús, Lafuente-Casanova Óscar, Salas Rosario, Rodríguez Carlota, Graciani-Pérez Miguel, Leonardo-Caserta Pablo Roque, López-Arroyo Manuel, Torres-Laborde Asunta, Gutiérrez-Rojas Luis
Аннотация
BACKGROUND: Paliperidone palmitate 6-month formulation (PP6M) offers a promising alternative for maintaining treatment adherence and reducing relapse risk in patients with schizophrenia. However, real-world data on its long-term effectiveness and safety remains limited.
AIMS: To evaluate the effectiveness and safety of PP6M in a real-world setting over 12 months in patients with schizophrenia previously stabilized on monthly (PP1M) or 3-monthly (PP3M) formulations.
METHODS: This was a multicenter, ambispective mirror-image study conducted across 10 Community Mental Health Units in Spain. A total of 158 patients with schizophrenia who switched from PP1M or PP3M to PP6M were followed at baseline, 6 months, and 12 months. Effectiveness was assessed through hospitalization rates, Clinical Global Impression (CGI), and Sheehan Disability Scale (SDS) scores. Safety, adverse effects, and substance use were also analyzed.
RESULTS: A significant reduction in hospitalization was observed at 6 and 12 months compared to the prior year. CGI and SDS scores improved significantly over time. Patient retention at 12 months was 83%, resulting in a dropout rate of 17%. The primary reasons for dropout were clinical relapse (40.7%) and patient refusal (29.6%). Adverse events were reported in 38.2% of patients, mostly mild or moderate. A significant reduction in substance use, particularly cocaine, was also noted. Acceptance of PP6M was high, with nursing staff playing a key role in facilitating the transition.
CONCLUSIONS: PP6M is an effective and well-tolerated option for patients with schizophrenia in real-world clinical practice. It reduces hospitalizations, improves clinical outcomes, and may contribute to decreased substance use.
AIMS: To evaluate the effectiveness and safety of PP6M in a real-world setting over 12 months in patients with schizophrenia previously stabilized on monthly (PP1M) or 3-monthly (PP3M) formulations.
METHODS: This was a multicenter, ambispective mirror-image study conducted across 10 Community Mental Health Units in Spain. A total of 158 patients with schizophrenia who switched from PP1M or PP3M to PP6M were followed at baseline, 6 months, and 12 months. Effectiveness was assessed through hospitalization rates, Clinical Global Impression (CGI), and Sheehan Disability Scale (SDS) scores. Safety, adverse effects, and substance use were also analyzed.
RESULTS: A significant reduction in hospitalization was observed at 6 and 12 months compared to the prior year. CGI and SDS scores improved significantly over time. Patient retention at 12 months was 83%, resulting in a dropout rate of 17%. The primary reasons for dropout were clinical relapse (40.7%) and patient refusal (29.6%). Adverse events were reported in 38.2% of patients, mostly mild or moderate. A significant reduction in substance use, particularly cocaine, was also noted. Acceptance of PP6M was high, with nursing staff playing a key role in facilitating the transition.
CONCLUSIONS: PP6M is an effective and well-tolerated option for patients with schizophrenia in real-world clinical practice. It reduces hospitalizations, improves clinical outcomes, and may contribute to decreased substance use.